TY - JOUR
T1 - Mucosal and hormonal adaptations after Roux-en-Y gastric bypass
AU - Feris, Fauzi
AU - McRae, Alison
AU - Kellogg, Todd A.
AU - McKenzie, Travis
AU - Ghanem, Omar
AU - Acosta, Andres
N1 - Funding Information:
A. Acosta is a stockholder in Gila Therapeutics and Phenomix Sciences; he also served as a consultant for Rhythm Pharmaceuticals and Amgen. A. Acosta is supported by the National Institutes of Health (NIH K23-DK114460). The NIH was not involved in the study design; in the collection, analysis, and interpretation of the study results; in the writing of the article; or in the decision to submit the article for publication.
Funding Information:
A. Acosta is a stockholder in Gila Therapeutics and Phenomix Sciences; he also served as a consultant for Rhythm Pharmaceuticals and Amgen. A. Acosta is supported by the National Institutes of Health (NIH K23-DK114460). The NIH was not involved in the study design; in the collection, analysis, and interpretation of the study results; in the writing of the article; or in the decision to submit the article for publication.
Publisher Copyright:
© 2023 American Society for Metabolic and Bariatric Surgery
PY - 2023/1
Y1 - 2023/1
N2 - The aim of this study was to perform a comprehensive literature review regarding the relevant hormonal and histologic changes observed after Roux-en-Y gastric bypass (RYGB). We aimed to describe the relevant hormonal (glucagon-like peptides 1 and 2 [GLP-1 and GLP-2], peptide YY [PYY], oxyntomodulin [OXM], bile acids [BA], cholecystokinin [CCK], ghrelin, glucagon, gastric inhibitory polypeptide [GIP], and amylin) profiles, as well as the histologic (mucosal cellular) adaptations happening after patients undergo RYGB. Our review compiles the current evidence and furthers the understanding of the rationale behind the food intake regulatory adaptations occurring after RYGB surgery. We identify gaps in the literature where the potential for future investigations and therapeutics may lie. We performed a comprehensive database search without language restrictions looking for RYGB bariatric surgery outcomes in patients with pre- and postoperative blood work hormonal profiling and/or gut mucosal biopsies. We gathered the relevant study results and describe them in this review. Where human findings were lacking, we included animal model studies. The amalgamation of physiologic, metabolic, and cellular adaptations following RYGB is yet to be fully characterized. This constitutes a fundamental aspiration for enhancing and individualizing obesity therapy.
AB - The aim of this study was to perform a comprehensive literature review regarding the relevant hormonal and histologic changes observed after Roux-en-Y gastric bypass (RYGB). We aimed to describe the relevant hormonal (glucagon-like peptides 1 and 2 [GLP-1 and GLP-2], peptide YY [PYY], oxyntomodulin [OXM], bile acids [BA], cholecystokinin [CCK], ghrelin, glucagon, gastric inhibitory polypeptide [GIP], and amylin) profiles, as well as the histologic (mucosal cellular) adaptations happening after patients undergo RYGB. Our review compiles the current evidence and furthers the understanding of the rationale behind the food intake regulatory adaptations occurring after RYGB surgery. We identify gaps in the literature where the potential for future investigations and therapeutics may lie. We performed a comprehensive database search without language restrictions looking for RYGB bariatric surgery outcomes in patients with pre- and postoperative blood work hormonal profiling and/or gut mucosal biopsies. We gathered the relevant study results and describe them in this review. Where human findings were lacking, we included animal model studies. The amalgamation of physiologic, metabolic, and cellular adaptations following RYGB is yet to be fully characterized. This constitutes a fundamental aspiration for enhancing and individualizing obesity therapy.
KW - Bariatric surgery
KW - Gastric bypass
KW - Gut hormones
KW - Metabolic adaptations
KW - Mucosal adaptations
KW - Obesity
KW - Roux-en-Y gastric bypass
KW - Satiety hormones
UR - http://www.scopus.com/inward/record.url?scp=85145017107&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85145017107&partnerID=8YFLogxK
U2 - 10.1016/j.soard.2022.08.020
DO - 10.1016/j.soard.2022.08.020
M3 - Review article
C2 - 36243547
AN - SCOPUS:85145017107
SN - 1550-7289
VL - 19
SP - 37
EP - 49
JO - Surgery for Obesity and Related Diseases
JF - Surgery for Obesity and Related Diseases
IS - 1
ER -